MYCO-004

MYCO-004

Clinical data
Other names	MYCO004
Routes of administration	Transdermal (patch)[1]
Drug class	Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

MYCO-004 is a patch-delivered psychedelic tryptamine which is under development for the treatment of psychiatric disorders.[2][3][1] It is anticipated to allow for precision dosing and to have a short duration of approximately 2 hours.[4] The drug is being developed by Mydecine.[2][3] As of December 2021, it is in preclinical research for psychiatric disorders.[2][3] The exact chemical structure of MYCO-004 does not yet seem to have been disclosed.[2]

See also

• MYCO-005
• List of investigational hallucinogens and entactogens

References

1. Psychedelic Alpha (10 January 2022). "Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds". Psychedelic Alpha. Retrieved 29 January 2025. This 5-HT2A receptor model is just the beginning of Mydecine's planned modeling in production that will continue to enhance their AI-driven drug discovery program. The Company's AI program has already led to identifying promising enhancements to psilocybin and psilocin which they have included in their recent patent application around MYCO-004, which directly addresses further precision in delivery control and shelf stabilization through a dermal route of administration. To learn more about the benefits of this second-generation psychedelic compound, read the Company's recent press release here.
2. "MYCO 004". AdisInsight. 15 December 2021. Retrieved 29 January 2025.
3. "Delving into the Latest Updates on MYCO-004 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
4. Psychedelic Alpha (24 June 2021). "Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004". Psychedelic Alpha. Retrieved 29 January 2025.